Cargando…

Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?

INTRODUCTION: The aim of the study is to investigate whether standard doses of rosiglitazone (4 mg/daily) and ramipril (5 mg/daily) can reverse pre-clinical macrovasculopathy in newly diagnosed never treated type 2 diabetes (T2DM) patients. METHODS: In this randomized, double-blind, placebo-controll...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahman, Sayeeda, Ismail, Aziz Al-Shafi, Ismail, Shaiful Bhari, Naing, Nyi Nyi, Rahman, Abdul Rashid Abdul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262381/
https://www.ncbi.nlm.nih.gov/pubmed/22291490
_version_ 1782221717992636416
author Rahman, Sayeeda
Ismail, Aziz Al-Shafi
Ismail, Shaiful Bhari
Naing, Nyi Nyi
Rahman, Abdul Rashid Abdul
author_facet Rahman, Sayeeda
Ismail, Aziz Al-Shafi
Ismail, Shaiful Bhari
Naing, Nyi Nyi
Rahman, Abdul Rashid Abdul
author_sort Rahman, Sayeeda
collection PubMed
description INTRODUCTION: The aim of the study is to investigate whether standard doses of rosiglitazone (4 mg/daily) and ramipril (5 mg/daily) can reverse pre-clinical macrovasculopathy in newly diagnosed never treated type 2 diabetes (T2DM) patients. METHODS: In this randomized, double-blind, placebo-controlled study, 33 T2DM patients were randomized to rosiglitazone (4 mg/daily) or ramipril (5 mg/daily) or placebo for 1 year. Hemodynamic variables were measured at 3 treatment phases and pulse wave velocity (PWV) and augmentation index (AI) were measured throughout the treatment period. RESULT: In diabetic patients, PWV (P = 0.037) and AI (P = 0.005) with ramipril and AI (P < 0.001) with rosiglitazone were significantly reduced during overall treatment period from the baseline; however, these differences were not significant in comparison to placebo. DISCUSSION AND CONCLUSION: The present study showed that treatment with standard doses of rosiglitazone and ramipril are not adequate to reverse pre-clinical vasculopathy in T2DM. The lack of benefit in newly diagnosed T2DM may be because of the relatively short-term intervention and/or the use of lower doses of rosiglitazone/ramipril. Further trials are needed for a longer period of time, possibly with higher doses, to show whether rosiglitazone/ramipril can reverse pre-clinical vasculopathy in T2DM (ClinicalTrials.gov number, NCT00489229).
format Online
Article
Text
id pubmed-3262381
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-32623812012-01-30 Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses? Rahman, Sayeeda Ismail, Aziz Al-Shafi Ismail, Shaiful Bhari Naing, Nyi Nyi Rahman, Abdul Rashid Abdul Clin Pharmacol Original Research INTRODUCTION: The aim of the study is to investigate whether standard doses of rosiglitazone (4 mg/daily) and ramipril (5 mg/daily) can reverse pre-clinical macrovasculopathy in newly diagnosed never treated type 2 diabetes (T2DM) patients. METHODS: In this randomized, double-blind, placebo-controlled study, 33 T2DM patients were randomized to rosiglitazone (4 mg/daily) or ramipril (5 mg/daily) or placebo for 1 year. Hemodynamic variables were measured at 3 treatment phases and pulse wave velocity (PWV) and augmentation index (AI) were measured throughout the treatment period. RESULT: In diabetic patients, PWV (P = 0.037) and AI (P = 0.005) with ramipril and AI (P < 0.001) with rosiglitazone were significantly reduced during overall treatment period from the baseline; however, these differences were not significant in comparison to placebo. DISCUSSION AND CONCLUSION: The present study showed that treatment with standard doses of rosiglitazone and ramipril are not adequate to reverse pre-clinical vasculopathy in T2DM. The lack of benefit in newly diagnosed T2DM may be because of the relatively short-term intervention and/or the use of lower doses of rosiglitazone/ramipril. Further trials are needed for a longer period of time, possibly with higher doses, to show whether rosiglitazone/ramipril can reverse pre-clinical vasculopathy in T2DM (ClinicalTrials.gov number, NCT00489229). Dove Medical Press 2010-04-20 /pmc/articles/PMC3262381/ /pubmed/22291490 Text en © 2010 Rahman et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Rahman, Sayeeda
Ismail, Aziz Al-Shafi
Ismail, Shaiful Bhari
Naing, Nyi Nyi
Rahman, Abdul Rashid Abdul
Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?
title Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?
title_full Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?
title_fullStr Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?
title_full_unstemmed Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?
title_short Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?
title_sort effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262381/
https://www.ncbi.nlm.nih.gov/pubmed/22291490
work_keys_str_mv AT rahmansayeeda effectofrosiglitazoneandramiprilonmacrovasculopathyinpatientswithtype2diabetesneedslongertreatmentandorhigherdoses
AT ismailazizalshafi effectofrosiglitazoneandramiprilonmacrovasculopathyinpatientswithtype2diabetesneedslongertreatmentandorhigherdoses
AT ismailshaifulbhari effectofrosiglitazoneandramiprilonmacrovasculopathyinpatientswithtype2diabetesneedslongertreatmentandorhigherdoses
AT naingnyinyi effectofrosiglitazoneandramiprilonmacrovasculopathyinpatientswithtype2diabetesneedslongertreatmentandorhigherdoses
AT rahmanabdulrashidabdul effectofrosiglitazoneandramiprilonmacrovasculopathyinpatientswithtype2diabetesneedslongertreatmentandorhigherdoses